Léim chuig an ábhar
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
CASTA
  • S110: PHALLCON: A PHASE 3 STUD...
  • Luaigh é seo
  • Seol mar théacs é seo
  • Seol é seo mar r-phost
  • Priontáil
  • Easpórtáil taifead
    • Easpórtáil chuig RefWorks
    • Easpórtáil chuig EndNoteWeb
    • Easpórtáil chuig EndNote
  • Buan-nasc
S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Elias Jabbour, Hagop Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gomez, Maria Baer, Carlo Gambacorti-Passerini, James Mccloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice Wang, Meliessa Hennessy, Niti Patel, Alexander Vorog, Bingxia Wang, Huilan Yao, Tammie Yeh, Josep Maria Ribera
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Wiley 2023-08-01
Sraith:HemaSphere
Rochtain ar líne:http://journals.lww.com/10.1097/01.HS9.0000967352.68516.d0
  • Stoc
  • Cur síos
  • Míreanna comhchosúla
  • Amharc foirne

Ar líne

http://journals.lww.com/10.1097/01.HS9.0000967352.68516.d0

Míreanna comhchosúla

  • PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
    de réir: E. Jabbour, et al.
    Foilsithe / Cruthaithe: (2022-06-01)
  • Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
    de réir: David Sanford, et al.
    Foilsithe / Cruthaithe: (2015-12-01)
  • The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
    de réir: Aziz Nazha, et al.
    Foilsithe / Cruthaithe: (2013-10-01)
  • Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts
    de réir: Preetesh Jain, et al.
    Foilsithe / Cruthaithe: (2013-11-01)
  • P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
    de réir: J. Apperley, et al.
    Foilsithe / Cruthaithe: (2022-06-01)

Roghanna cuardaigh

  • Stair cuardach
  • Cuardach Casta

Aimsigh tuilleadh

  • Brabhsáil an chatalóg
  • Brabhsáil in ord aibítre
  • Breathnaigh ar chainéil
  • Áirithintí cúrsa
  • Míreanna nua

Cabhair uait?

  • Leideanna cuardaigh
  • Cuir ceist ar leabharlannaí
  • CCanna